This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cui, L.
Right arrow Articles by Hiramatsu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cui, L.
Right arrow Articles by Hiramatsu, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 1231-1234, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01173-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus{triangledown}

Longzhu Cui,1,2* Hui-min Neoh,1,{dagger} Mitsutaka Shoji,2 and Keiichi Hiramatsu1,2

Department of Bacteriology,1 Department of Infection Control Science, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan2

Received 3 September 2008/ Returned for modification 2 November 2008/ Accepted 27 December 2008


arrow
ABSTRACT
 
We describe here the genetic analysis of a vancomycin-susceptible Staphylococcus aureus (VSSA) strain, Mu50{Omega}, a strain related to vancomycin-intermediate S. aureus (VISA) strain Mu50. Using a combination of Mu50{Omega} whole-genome sequencing and genome engineering, we observed a stepwise evolution of vancomycin resistance from VSSA to VISA after the mutated vraS and graR genes of Mu50 were engineered into Mu50{Omega}.


arrow
INTRODUCTION
 
The major human pathogen Staphylococcus aureus poses a significant public health threat and is becoming increasingly resistant to currently available antibiotics, including vancomycin, which is the frontline drug for methicillin-resistant S. aureus infections (2, 10). Vancomycin-intermediate Staphylococcus aureus (VISA) is considered to have emerged from vancomycin-susceptible Staphylococcus aureus (VSSA) through multiple genetic alterations (4, 9). We have recently reported that a mutated response regulator gene, graR, of VISA Mu50 could convert the hetero-VISA Mu3 into a VISA strain when it is overexpressed in Mu3 (4, 16). Here, we report a follow-up study with the genetic analysis and engineering of a vancomycin-susceptible clinical S. aureus strain, Mu50{Omega}, related to Mu50.

Mu50{Omega} was isolated from the patient from whom strain Mu50 had been isolated one and a half years before. The patient was hospitalized because of a relapsed surgical site infection, and the vancomycin-susceptible strain was identified among VISA isolates indistinguishable from Mu50. Despite its vancomycin susceptibility, the strain possessed the same pulsed-field gel electrophoresis pattern as Mu50; thus, we named it Mu50{Omega}, suspecting its close relationship with Mu50 (5, 13).

To understand the genetic basis behind Mu50{Omega}'s vancomycin susceptibility, we determined whole-genome sequence of Mu50{Omega}. Genome sequencing was performed using the chromosome-walking method with Mu50 genome sequence (accession no. BA000017) as a scaffold for primer design as well as orientation of the contiguous PCR fragments of Mu50{Omega}. A 2,878,428-bp-long whole-genome sequence of Mu50{Omega} with the same general features of Mu50 genome (14), including G+C content, rRNA operon, tRNA, transfer-messenger RNA, IS431, Tn554, SCCmec, bacteriophage, and genomic island, was successfully determined. The resulting sequence was then used for genome comparison with Mu50, and loci containing nucleotide differences between Mu50{Omega} and Mu50 chromosomes including single nucleotide polymorphisms (SNPs) or deletion/insertion regions were identified. All nucleotide differences were confirmed by resequencing the corresponding regions of Mu50{Omega} and Mu50 genomic DNAs. With this, we finally confirmed that there were only a total of 10 SNPs and 3 deletions/insertions which would cause, in either Mu50 or Mu50{Omega}, a single-amino-acid replacement in the products of four genes, a premature termination of the products of two genes, and a total or partial deletion of four genes (Table 1). These differences were considered as candidates responsible for differences in vancomycin susceptibility between VISA Mu50 and VSSA Mu50{Omega}. In particular, differences in the vraSR (12) and graSR (4) two-component regulator systems, which are reported to be highly related to vancomycin resistance (4, 7, 11, 12, 15, 17), were evident. The vraS of Mu50{Omega} differed from that of Mu50 for the presence of a premature stop codon (Fig. 1A). Besides, both Mu50 vraS and Mu50{Omega} vraS had a T->A transition at nucleotide position 14, generating an Ile5->Asn5 substitution, compared to the vraS genes of VSSA N315 and 12 other VSSA strains for which genomes have been published (Table 1 and Fig. 1A). Concerning graSR, graR of Mu50{Omega} lacked the mutation identified in Mu50 (Table 1 and Fig. 1A) (4, 16).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Differences between the Mu50{Omega} and Mu50 genomes


Figure 1
View larger version (21K):
[in this window]
[in a new window]

  		FIG. 1. vraS and graR sequence alignment and vancomycin resistance profiles for Mu50{Omega} and its genetically engineered derivatives. (A) Partial sequence alignment of vraS (left panel) and graR (right panel) polymorphic loci. (B) Distribution profiles of vancomycin-resistant subpopulations against various vancomycin concentrations.

To prove the significance of the above mutations in vancomycin susceptibility, we engineered the VSSA Mu50{Omega} strain stepwise, with individual genetic traits of N315 or Mu50. Briefly, this was carried out by removing the stop codon from the Mu50{Omega} vraS and subsequently adding the Mu50-specific nonsynonymous mutation into its graR gene, using the plasmid pKOR1-mediated substitution technique as described previously (1, 16). A total of three Mu50{Omega} mutants were constructed: (i) Mu50{Omega}-vraSn, which had replacement of Mu50{Omega} vraS with N315 vraS; (ii) Mu50{Omega}-vraSm, which had replacement of Mu50{Omega} vraS with Mu50 vraS; and (iii) Mu50{Omega}-vraSm-graRm, which had replacement of Mu50{Omega} vraS and graR with Mu50 vraS and Mu50 graR (Fig. 1A). With each step of the above construction, we observed a stepwise increase of vancomycin resistance, from VSSA to the VISA phenotype. MIC determination demonstrated that the resulting constructs had remarkable increases in vancomycin MIC, from 0.5 mg/liter for Mu50{Omega} to 3.5 mg/liter for Mu50{Omega}-vraSn, 4.5 mg/liter for Mu50{Omega}-vraSm, and 6 mg/liter for Mu50{Omega}-vraSm-graRm (the latter value is equivalent to that of Mu50). Consistent with the increased vancomycin MICs, population analysis showed that Mu50{Omega}-vraSn and Mu50{Omega}-vraSm had a significant increase in vancomycin-resistant subpopulations compared to the parent strain Mu50{Omega}, and Mu50{Omega}-vraSm-graRm had almost the same vancomycin resistance profile as Mu50 (Fig. 1B), exhibiting the conversion of VSSA Mu50{Omega} into a VISA strain. Toward other antibiotics targeting cell wall synthesis, including teicoplanin, bacitracin, and β-lactams, the mutants also showed significant decreased susceptibility, whereas no changes were observed in the susceptibility to other antibiotic groups—e.g., aminoglycosides, quinolones, and tetracyclines (Table 2) —indicating that the genome engineering of vraS and graR mutations did not affect Mu50{Omega}'s susceptibility profile toward non-cell-wall-associated antibiotics. Altogether, it is interesting to note that (i) loss of vancomycin resistance in Mu50{Omega} is due to the truncated translation of VraS protein; (ii) full translation of VraS protein seems to be indispensable for the resistance to cell-wall-associated antibiotics; (iii) restoration of vraS function alone did not raise vancomycin resistance of Mu50{Omega} to the level of VISA Mu50; and (iv) a subsequent point mutation in graR is needed for the enhancement of vancomycin resistance in a Mu50{Omega} clone with a mutated vraS to reach that of Mu50.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Antibiotic susceptibility profiles of S. aureus strains used in this study

This study clearly revealed that direct engineering of the Mu50{Omega} genome with Mu50 vraS partially restores its vancomycin resistance, and with a further Mu50 graR substitution on the mutant's chromosome, a vancomycin resistance level similar to that of Mu50 is achieved. This reconfirmed our view that activation of VraSR and GraSR two-component regulatory systems in VSSA will lead to a VISA phenotype through the activation of the genes under their regulation (13, 16).

The two-component regulator systems vraSR and graSR were identified as glycopeptide resistance-associated genes in previous studies (4, 12) and are known to positively modulate the regulation of cell wall biosynthesis (11, 12, 16). Cell wall thickening is the molecular mechanism of vancomycin resistance in VISA, which is associated with the peptidoglycan-clogging mechanism that prevents the passage of vancomycin through a thickened peptidoglycan layer (3, 5, 6, 8). VraSR is known to be important in the uptake of materials needed for cell wall synthesis (12), and the activation of vraSR, which upregulates the expression of enzymes involved in the peptidoglycan synthesis pathway such as PBP2, PBP1A/1B, MurZ, etc., could occur by a single point mutation in vraS (Y. Katayama et al., submitted for publication). Overexpression of mutated graR, designated graRm ("m" stands for Mu50), in a vraSR-activated strain, hetero-VISA Mu3, raised vancomycin MIC and cell wall thickness significantly, while introduction of the intact graR into Mu3 did not increase vancomycin MIC and cell wall thickness appreciably (16). No significant increase was observed in vancomycin MIC and cell wall thickness when graRm was introduced into N315 that has an intact vraS (16). Although detailed studies on the physiological function and activation mechanism of vraSR and graSR are necessary, the data presented in this study clearly indicate that the combination effect of graSR and vraSR mutations found in VISA Mu50 contributes to vancomycin resistance. Nevertheless, whether the role of vraSR and graSR found in the Mu50 cell lineage could be applied to other clinical VISA strains in VISA phenotype conversion remains to be investigated.


arrow
Nucleotide sequence accession number.
 
The nucleotide sequences determined in this work were submitted to the DDBJ database and assigned accession no. BABM01000001.


arrow
ACKNOWLEDGMENTS
 
We thank T. Bae for providing us with plasmid pKOR1 and F. Takeuchi for help with genome comparison.

This work was supported by a Grant-in-Aid for 21st Century COE Research to K. Hiramatsu and Grant-in-Aid for Scientific Research 18590438 to L. Cui from The Ministry of Education, Science, Sports, Culture and Technology of Japan.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Bacteriology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan. Phone: (3) 5802-1041. Fax: (3) 5684-7830. E-mail: longzhu{at}juntendo.ac.jp Back

{triangledown} Published ahead of print on 5 January 2009. Back

{dagger} Present address: UKM Medical Molecular Biology Institute, University Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia. Back


arrow
REFERENCES
 
    1
  1. Bae, T., and O. Schneewind. 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55:58-63.[Medline]
    2. 2
  2. Cui, L., and K. Hiramatsu. 2003. Vancomycin-resistant Staphylococcus aureus, p. 187-212. In A. C. Fluit and F. J. Schmitz (ed.), MRSA: current perspectives. Caister Academic Press, Norfolk, England.
    3. 3
  3. Cui, L., A. Iwamoto, J.-Q. Lian, H.-M. Neoh, T. Maruyama, Y. Horikawa, and K. Hiramatsu. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438.[Abstract/Free Full Text]
    4. 4
  4. Cui, L., J.-Q. Lian, H.-M. Neoh, E. Reyes, and K. Hiramatsu. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3404-3413.[Abstract/Free Full Text]
    5. 5
  5. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M.-N. Kim, M.-C. Ploy, N. El-Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.[Abstract/Free Full Text]
    6. 6
  6. Cui, L., H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285.[Abstract/Free Full Text]
    7. 7
  7. Gardete, S., S. W. Wu, S. Gill, and A. Tomasz. 2006. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:3424-3434.[Abstract/Free Full Text]
    8. 8
  8. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.[CrossRef][Medline]
    9. 9
  9. Hiramatsu, K., L. Cui, and K. Kuwahara-Arai. 2004. Has vancomycin-resistant Staphylococcus aureus started going it alone? Lancet 364:565-566.[CrossRef][Medline]
    10. 10
  10. Hiramatsu, K., M. Kapi, Y. Tajima, L. Cui, S. Trakulsomboon, and T. Iso. 2004. Advances in vancomycin resistance: research in Staphylococcus aureus, p. 289-298. In M. Alekshun, P. McDermott, and D. White (ed.), Frontiers in antibiotic resistance: a tribute to Stuart B. Levy. ASM Press, Washington, DC.
    11. 11
  11. Howden, B. P., T. P. Stinear, D. L. Allen, P. D. R. Johnson, P. B. Ward, and J. K. Davies. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3755-3762.[Abstract/Free Full Text]
    12. 12
  12. Kuroda, M., H. Kuroda, T. Oshima, F. Takeuchi, H. Mori, and K. Hiramatsu. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49:807-821.[CrossRef][Medline]
    13. 13
  13. Kuroda, M., K. Kuwahara-Arai, and K. Hiramatsu. 2000. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem. Biophys. Res. Commun. 269:485-490.[CrossRef][Medline]
    14. 14
  14. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.[CrossRef][Medline]
    15. 15
  15. Meehl, M., S. Herbert, F. Götz, and A. Cheung. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679-2689.[Abstract/Free Full Text]
    16. 16
  16. Neoh, H.-M., L. Cui, H. Yuzawa, F. Takeuchi, M. Matsuo, and K. Hiramatsu. 2008. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52:45-53.[Abstract/Free Full Text]
    17. 17
  17. Yin, S., R. S. Daum, and S. Boyle-Vavra. 2006. VraSR two-component regulatory system and its role in induction of pbp2 and vraSR expression by cell wall antimicrobials in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:336-343.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, March 2009, p. 1231-1234, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01173-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kato, Y., Suzuki, T., Ida, T., Maebashi, K. (2009). Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. J Antimicrob Chemother 0: dkp394v1-dkp394 [Abstract] [Full Text]  
  • Katayama, Y., Murakami-Kuroda, H., Cui, L., Hiramatsu, K. (2009). Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem. Antimicrob. Agents Chemother. 53: 3190-3196 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cui, L.
Right arrow Articles by Hiramatsu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cui, L.
Right arrow Articles by Hiramatsu, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»